Background. The increase in multidrug-resistant tuberculosis (MDR-TB) severely hampers tuberculosis prevention and control in China, a country with the second highest MDR-TB burden globally. The first nationwide drug-resistant tuberculosis surveillance program provides an opportunity to comprehensively investigate the epidemiological/drug-resistance characteristics, potential drug-resistance mutations, and effective population changes of Chinese MDR-TB.
drug-resistance characteristics [2] [3] [4] , potential drug-resistance mutations [5] [6] [7] , and evolution of MDR-TB [8, 9] .
Although previous studies have revealed some features of MDR-TB in China, the first nationwide drug-resistant tuberculosis surveillance in China (covering 70 counties in 31 provinces) [10] provided a great opportunity for comprehensive investigation of the epidemiological/drug-resistance characteristics, drug-resistance genes/single-nucleotide polymorphisms (SNPs), and evolution of MDR-TB in China. Here, we performed whole-genome sequencing (WGS) for 357 MDR-TB strains from the survey. Drug-susceptibility testing (DST) was also conducted using 18 anti-tuberculosis drugs, representing the most comprehensive drug-resistance profile to date. Through the comprehensive analyses of epidemiological/ drug-resistance phenotypic and genotypic data, we describe the epidemiological/drug-resistance characteristics, potential drug-resistance genes/intergenic regions (IGRs)/SNPs, and the effective population changes of MDR-TB in China.
METHODS

Sample Information and Sequencing
The first national survey of drug-resistant tuberculosis in China (2007) (2008) included local/regional surveys (covering 70 counties in 31 provinces) by the Chinese Center for Disease Control and Prevention [10] . Cluster-randomized sampling was adopted to obtain representative samples of patients with tuberculosis in China [10] . The number of study participants was estimated at 3542 treatment naive patients and 1189 previously treated patients (Supplementary Table 1 ). Finally, 4600 representative sputum samples from smear-positive tuberculosis (3514 treatment naive and 1086 previously treated patients) cases were obtained. Written informed consent was also obtained from each patient in face-to-face interviews by trained clinicians.
After excluding 671 samples (culture failed to grow, 531; non-tuberculous mycobacteria, 140), we successfully obtained 3929 Mycobacterium tuberculosis isolates, which were preserved in the Beijing Bio-Bank of Clinical Resources on Tuberculosis (Beijing Chest Hospital, China). Through DST, we obtained 401 MDR isolates. Eliminating 28 samples that failed to regrow, 373 MDR strains were obtained for sequencing (Figure 1 ). Sixtyseven non-MDR control strains were also selected from the first national survey of drug-resistant tuberculosis in China according to distribution of MDR strains (Supplementary Table 2 ).
The above strains were cultivated on Lowenstein-Jensen solid media. Genomic DNA samples were prepared and purified for sequencing using the MasterPure Complete DNA isolation kit (Epicentre, Madison, WI) following the standard protocols. DNA libraries were constructed using kits provided by Illumina according to the manufacturer's instructions. Sequencing was performed on an Illumina HiSeq X-Ten sequencing platform. After excluding 16 problematic genomes, 357 MDR-TB genomes were used for subsequent bioinformatics analysis. For additional information, see the Supplementary Methods. The drug-susceptible tests were performed using 18 anti-tuberculosis drugs. R indicates the number of resistance strains, S indicates the number of susceptible strains, and NA indicates the number of the strains with failed drug-susceptibility testing. Some screening procedures were completed as reported in the literature (denoted as *). B, Nationwide distribution of MDR isolates from the first national survey of drug-resistant tuberculosis in China. The shade of color indicates the number of MDR strains. Abbreviations: AMK, amikacin; BDQ, bedaquiline; CFZ, clofazimine; CPM, capreomycin; CS, cycloserine; DEL, delamanid; EMB, ethambutol; ETO, ethionamide; H1, high-dose isoniazid; INH, isoniazid; KM, kanamycin; LZD, linezolid; MDR, multidrug-resistant; MOX, moxifloxacin; Mtb, Mycobacterium tuberculosis; OFX, ofloxacin; PAS, para-aminosalicylic acid; PZA, pyrazinamide; RIF, rifampicin; SM, streptomycin.
Drug Susceptibility Testing
The DST for 18 anti-tuberculosis drugs was performed with solid medium or an MGIT 960 system (BD Biosciences, Sparks, MD) using methods recommended by WHO or in other studies [11] [12] [13] [14] [15] . Bedaquiline, delamanid, and clofazimine were purchased from the Hanxiang Company (Shanghai, China); the other drugs were purchased from Sigma-Aldrich. DST methods are shown in Supplementary Table 3 .
SNP Identification and Phylogenetic Analyses
Sequencing reads for the strains were aligned to the H37Rv reference genome (NC_000962) using SOAP2 [16] and the Burrows-Wheeler algorithm [17] (average coverage, >98%; average depth, 325×). SNPs were derived from high-quality unique mapping reads using SOAPsnp [16] , SAMtools [18] , and GATK [19] . Further filtration was performed based on the standards in the literature [20] . The 34 959 SNPs (excluding the SNPs within the known drug-resistance genes [21] and repeat regions [22] ) in all strains were used to construct a phylogenetic tree using FastTree v2.1.9 [23] . Mycobacterium canettii CIPT 140010059 was used as an outlier (Supplementary Figure 1) . Genotyping was implemented based on 62 SNP markers [24] .
Identification of Potential Drug-resistance SNPs and Genes/IGRs
We used the following 4 identification methods: normal distribution analysis [6] , Fisher exact test [11] , PhyC test [7] , and random forest model [25] . To ensure reliability, only the genes/ IGRs/SNPs identified by at least 3 methods and with the proportion of drug-sensitive isolates less than 0.3 were considered as potentially drug-resistant candidates. The detailed protocols are provided in the Supplementary Methods.
Bayesian Skyline Analyses of MDR-TB
To evaluate the changes in effective population size since 1974 (when rifampicin was brought to the market in China), we performed Bayesian skyline analysis for the 357 MDR-TB strains based on the concatenated SNPs in the identified resistance genes/IGRs using BEAST v1.8.4 [26] (for details, see the Supplementary Methods).
Data Availability
Whole-genome sequencing raw data were deposited at Sequence Read Archive (SRP134826) and Genome Sequence Archive (CRA000786).
RESULTS
Epidemiological Characteristics of MDR-TB in China
The 357 MDR strains were screened from the 3929 M. tuberculosis isolates in the first national survey of drug-resistant tuberculosis (70 counties in 31 provinces). These data are still the most representative Chinese MDR strains to date (Figure 1 and  Supplementary Table 4) . Sixty-seven non-MDR control strains were also selected from the survey according to distribution of MDR strains (Supplementary Table 5 ).
The corresponding patient information is shown in Table 1  and Supplementary Tables 4 and 5 . As previously reported [10] , the most prevalent MDR strains in China were lineage 2 Beijing strains (293, 82.1%; Figure 2) 
Drug-resistance Characteristics of MDR-TB in China
We performed the DSTs for 18 anti-tuberculosis drugs (Supplementary Table 3 ). The drug-resistance profiles are shown in Supplementary Table 6 . We first calculated the resistance ratio of each anti-tuberculosis drug in MDR strains (Table 1, Supplementary Table 7 , and Supplementary Figure 2) . The results revealed that the resistance ratio of pyrazinamide (38.1%) was the lowest among the first-line drugs. Subsequent analysis of the resistance ratios for the other drugs showed that they were much lower than those for the first-line drugs in the following ranking order (from low to high): bedaquiline (0.8%) < delamanid (1.4%) < linezolid (2.8%) < clofazimine (7.0%) < capreomycin (9.2%) < amikacin (9.5%) < kanamycin (10.6%) < para-aminosalicylic acid (11.8%) < moxifloxacin (13.45%) < cycloserine (13.7%) < ethionamide (21.3%) < ofloxacin (26.9%).
We further investigated the distribution of MDR-TB strains in China by calculating the proportion of MDR-TB strains with different drug-resistance profiles among the 7 administrative regions ( Figure 3A) . The results showed that more than half of MDR strains were resistant to at least 5 anti-tuberculosis drugs in each administrative region, especially in Northern (22%), Eastern (20%), Northwest (26%), and Southwest (29%) China, with more than 20% of MDR strains resistance to at least 8 drugs. This demonstrated severe drug resistance in China.
We then used the Fisher test to investigate the multidrug co-resistance patterns among the 7 Chinese administrative regions by constructing co-resistance relationship matrices for 15 anti-tuberculosis drugs ( Figure 3B ). In general, the 5 first-line anti-tuberculosis drugs showed a high frequency of co-resistance; the other anti-tuberculosis drugs displayed low frequency of co-resistance except for the 2 fluoroquinolones. Specifically, the MDR strains of each administrative region possessed their own characteristic co-resistance pattern. The MDR isolates in Northeast China displayed a high frequency of co-resistance to only 4 first-line drugs (isoniazid, rifampicin, streptomycin, and ethambutol) and low frequency of co-resistance to the other drugs. In contrast, the MDR isolates from Eastern China exhibited a high frequency of co-resistance to almost all anti-tuberculosis drugs except for linezolid and clofazimine. In addition, we also found a high frequency of co-resistance to 3 injectable anti-tuberculosis drugs in Northern, Central, and Southern China. The various multidrug co-resistance patterns might reflect different drug combinations/use preferences and other unmeasured variables in different regions.
Identification of Potential Drug-resistance SNPs and Genes/IGRs
To investigate the relationship between the drug-resistance phenotypes and genotypes of the 357 MDR-TB strains, we sequenced them using the Illumina HiSeq sequencing platform (average coverage, 325×; Supplementary Table 8) and applied 4 methods (3 statistical and 1 machine-learning [27] , which cover most of the well-known drug-resistance SNPs and genes/IGRs ( Figure 4 and Supplementary Tables 19 and 20) , indicating the credibility of our screening strategy. Importantly, we identified 31 new drug-resistance genes/IGRs. Their functions were mainly associated with the known drug-resistance mechanisms of M. tuberculosis, such as cell wall synthesis and fatty acid metabolism (8 genes), secretion/transport (4 genes), DNA replication/repair (3 genes), oxidoreductase (1 gene), transcription/translation (1 IGR), and proline-glutamic acid (PE)/ proline-proline-glutamic acid (PPE)-family genes (6 genes) (Supplementary Table 21 ). These genes/IGRs provide some potential molecular targets for the prevention and treatment of tuberculosis. We also validated our screening strategy by analyzing the nonsynonymous to synonymous substitutions (Ka/Ks) ratios of 33 drug-resistance genes (excluding 11 drug-resistance IGRs) that were subject to a higher selection pressure. We observed that these genes were under positive selection with Ka/Ks >1 in the MDR strains relative to the ratio of approximately 0.4 for other genes (Supplementary Figure 4) . These findings are consistent with those from a previous study [6] and further support the feasibility and accuracy of our screening strategy in identifying drug-resistance genes.
Compensatory Mutation
Previous studies have shown that some particular mutations of rpoA and rpoC compensate for fitness costs in rifampicin-resistant strains with rpoB mutations [28] . Here, we identified 38 potential compensatory mutations in rpoA and rpoC [20, 28] , 16 of which have not been reported previously. Thirty-seven compensatory mutations are associated with RpoB S450L, including 15 novel mutations. A "hot-spot" compensatory mutation region in rpoC has also been discovered (Supplementary Figure 5) as previous reported [29] . Incidentally, we found 2 pairs of potential compensatory mutations in RpoA and RpoC that co-occurred with RpoB S450L (RpoA E274G and RpoC E1033A; RpoA P250L and RpoC L527V; Supplementary  Table 22) . 
Changes in Effective Population
DISCUSSION
Our findings elucidate the epidemiological/drug-resistance characteristics, some potential drug-resistance genes/SNPs, and effective population changes of MDR tuberculosis in China. We did this by analyzing the epidemiological, drug-resistance phenotypic, and genotypic data of 357 MDR-TB strains from the first national survey of drug-resistant tuberculosis. Here, we evaluated data with important recommendations for precision medicine and future research, as discussed below. The resistance ratios of the anti-tuberculosis drugs also provide important reference to regimens for treatment of MDR-TB. As for the 2 fluoroquinolones we tested, moxifloxacin showed a lower resistance ratio (13.45%) than ofloxacin (26.9%). According to the longer MDR-TB regimens included in WHO evidence-based guidelines, moxifloxacin is also one of the prioritized medicines based on the latest evidence that refer to the balance of effectiveness to safety [30] . Importantly, bedaquiline (0.8%), delamanid (1.4%), and linezolid (2.8%) exhibited the lowest drug-resistance ratios. At present, bedaquiline and linezolid are considered prioritized medicines in the WHO guidelines for treatment of MDR-TB [30] . Bedaquiline is strongly recommended because of its effectiveness and low toxicity [31] . Linezolid also shows effectiveness but has limitations due to its high toxicity [30] . Although delamanid exhibited a low drug-resistance ratio, it did not belong to the prioritized group of medicines for treatment of MDR tuberculosis due to its short time to market and uncertain safety and effectiveness beyond 6 months [30] . These 3 drugs are rarely used in China currently and may constitute the last line of defense against MDR-TB; therefore, their prescription should be cautiously administered by clinicians.
Importantly, the 357 nationally representative MDR strains offered an opportunity to investigate the changes in MDR-TB population size in China since 1974, reflecting some realities during socioeconomic transition. The strong population expansion of Chinese MDR-TB strains during 1993-2000 might be predominantly associated with rapid economic growth [32] and incomplete tuberculosis surveillance and control systems during that period of socioeconomic transition. Rapid economic growth in the 1990s was accompanied by increased population movements from 21.3 million (1990) to 121 million (2000) ( Figure 5B ) [32] , contributing to significant MDR-TB transmission and expansion. Additionally, reduced patient compliance with tuberculosis treatment, antibiotic abuse, and sharp increases in the number of drug addicts and human immunodeficiency virus-infected individuals are also likely to have contributed to the transmission and spread of Chinese MDR-TB [33, 34] . Furthermore, the coverage of the DOTS course for tuberculosis was only 68% in 2000 [35] ( Figure 5B ).
The increase in the size of the Chinese MDR-TB population from 1993-2000 was restrained, while it remained unchanged from 2000 to 2006, and there was even had a significant decline after 2006. The proportion of MDR-TB in all tuberculosis cases also showed a sharp decrease from 2000 (10.7%) to 2010 (6.8%) [36, 37] . This favorable change in combating tuberculosis was mainly ascribed to the advances in new diagnostic techniques and anti-tuberculosis drugs, as well as increased government support for MDR-TB patients [1] . The Chinese government introduced a policy for free diagnostic tests and drug use for tuberculosis patients in 2004, which effectively reduced the economic burden on patients and improved their treatment compliance [38] . The national tuberculosis program budget was also increased from $98 million (2002) to $272 million (2007) [35] (Figure 5B ). The coverage of DOTS also reached 100% in 2005 [35] . Importantly, the government has provided an additional budget for MDR-TB since 2006, including subsidies for second-line drugs [35] . The WHO published guidelines for management of drug-resistant tuberculosis in 2006 (version 1), which also provide important guidance and advice for the prevention and control of MDR-TB in China [39] .
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